Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States
In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series. Data on patients started on bedaquiline for MDR TB...
Uloženo v:
| Vydáno v: | Clinical infectious diseases Ročník 71; číslo 4; s. 1010 |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
14.08.2020
|
| Témata: | |
| ISSN: | 1537-6591, 1537-6591 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series.
Data on patients started on bedaquiline for MDR TB between September 2012 and August 2016 were collected retrospectively through 4 TB programs using a standardized abstraction tool. Data were analyzed using univariate methods. Adverse events were graded using the Common Terminology Criteria for Adverse Events.
Of 14 patients, 7 (50%) had MDR, 4 (29%) had pre-extensively drug-resistant (XDR), and 3 (21%) had XDR TB. All had pulmonary TB, 5 (36%) had pulmonary and extrapulmonary TB, and 9/13 (69%) were smear positive. One patient (7%) had HIV coinfection, 5 (36%) had diabetes mellitus, and 5/14 (36%) had previous treatment TB. All patients were non-US-born and 5/14 (36%) had private insurance. All patients achieved sputum culture conversion within a mean of 71 days (26-116); 5 after starting bedaquiline. Twelve (86%) completed treatment and 1 (7%) moved out of the country. One patient (7%) had QTc prolongation >500 milliseconds and died 20 months after discontinuing bedaquiline of a cause not attributable to the drug. Common adverse events were peripheral neuropathy 7/14 (50%), not customarily associated with bedaquiline use, and QTc prolongation 6/14 (43%).
Of 14 patients, 1 (7%) had an adverse event necessitating bedaquiline discontinuation. Safety, culture conversion, and treatment completion in this series (7%) support use of bedaquiline for the treatment of MDR/XDR TB. |
|---|---|
| AbstractList | In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series.
Data on patients started on bedaquiline for MDR TB between September 2012 and August 2016 were collected retrospectively through 4 TB programs using a standardized abstraction tool. Data were analyzed using univariate methods. Adverse events were graded using the Common Terminology Criteria for Adverse Events.
Of 14 patients, 7 (50%) had MDR, 4 (29%) had pre-extensively drug-resistant (XDR), and 3 (21%) had XDR TB. All had pulmonary TB, 5 (36%) had pulmonary and extrapulmonary TB, and 9/13 (69%) were smear positive. One patient (7%) had HIV coinfection, 5 (36%) had diabetes mellitus, and 5/14 (36%) had previous treatment TB. All patients were non-US-born and 5/14 (36%) had private insurance. All patients achieved sputum culture conversion within a mean of 71 days (26-116); 5 after starting bedaquiline. Twelve (86%) completed treatment and 1 (7%) moved out of the country. One patient (7%) had QTc prolongation >500 milliseconds and died 20 months after discontinuing bedaquiline of a cause not attributable to the drug. Common adverse events were peripheral neuropathy 7/14 (50%), not customarily associated with bedaquiline use, and QTc prolongation 6/14 (43%).
Of 14 patients, 1 (7%) had an adverse event necessitating bedaquiline discontinuation. Safety, culture conversion, and treatment completion in this series (7%) support use of bedaquiline for the treatment of MDR/XDR TB. In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series.BACKGROUNDIn 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series.Data on patients started on bedaquiline for MDR TB between September 2012 and August 2016 were collected retrospectively through 4 TB programs using a standardized abstraction tool. Data were analyzed using univariate methods. Adverse events were graded using the Common Terminology Criteria for Adverse Events.METHODSData on patients started on bedaquiline for MDR TB between September 2012 and August 2016 were collected retrospectively through 4 TB programs using a standardized abstraction tool. Data were analyzed using univariate methods. Adverse events were graded using the Common Terminology Criteria for Adverse Events.Of 14 patients, 7 (50%) had MDR, 4 (29%) had pre-extensively drug-resistant (XDR), and 3 (21%) had XDR TB. All had pulmonary TB, 5 (36%) had pulmonary and extrapulmonary TB, and 9/13 (69%) were smear positive. One patient (7%) had HIV coinfection, 5 (36%) had diabetes mellitus, and 5/14 (36%) had previous treatment TB. All patients were non-US-born and 5/14 (36%) had private insurance. All patients achieved sputum culture conversion within a mean of 71 days (26-116); 5 after starting bedaquiline. Twelve (86%) completed treatment and 1 (7%) moved out of the country. One patient (7%) had QTc prolongation >500 milliseconds and died 20 months after discontinuing bedaquiline of a cause not attributable to the drug. Common adverse events were peripheral neuropathy 7/14 (50%), not customarily associated with bedaquiline use, and QTc prolongation 6/14 (43%).RESULTSOf 14 patients, 7 (50%) had MDR, 4 (29%) had pre-extensively drug-resistant (XDR), and 3 (21%) had XDR TB. All had pulmonary TB, 5 (36%) had pulmonary and extrapulmonary TB, and 9/13 (69%) were smear positive. One patient (7%) had HIV coinfection, 5 (36%) had diabetes mellitus, and 5/14 (36%) had previous treatment TB. All patients were non-US-born and 5/14 (36%) had private insurance. All patients achieved sputum culture conversion within a mean of 71 days (26-116); 5 after starting bedaquiline. Twelve (86%) completed treatment and 1 (7%) moved out of the country. One patient (7%) had QTc prolongation >500 milliseconds and died 20 months after discontinuing bedaquiline of a cause not attributable to the drug. Common adverse events were peripheral neuropathy 7/14 (50%), not customarily associated with bedaquiline use, and QTc prolongation 6/14 (43%).Of 14 patients, 1 (7%) had an adverse event necessitating bedaquiline discontinuation. Safety, culture conversion, and treatment completion in this series (7%) support use of bedaquiline for the treatment of MDR/XDR TB.CONCLUSIONSOf 14 patients, 1 (7%) had an adverse event necessitating bedaquiline discontinuation. Safety, culture conversion, and treatment completion in this series (7%) support use of bedaquiline for the treatment of MDR/XDR TB. |
| Author | Seaworth, Barbara Shah, Neha Mase, Sundari Chorba, Terence Dworkin, Felicia Belanger, Ann Warkentin, Jon Parks, Samuel Barry, Pennan |
| Author_xml | – sequence: 1 givenname: Sundari surname: Mase fullname: Mase, Sundari organization: World Health Organization, India Country Office, Delhi, India – sequence: 2 givenname: Terence surname: Chorba fullname: Chorba, Terence organization: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA – sequence: 3 givenname: Samuel surname: Parks fullname: Parks, Samuel organization: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA – sequence: 4 givenname: Ann surname: Belanger fullname: Belanger, Ann organization: Tuberculosis Control Branch, California Department of Public Health, Richmond, California, USA – sequence: 5 givenname: Felicia surname: Dworkin fullname: Dworkin, Felicia organization: Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, New York, USA – sequence: 6 givenname: Barbara surname: Seaworth fullname: Seaworth, Barbara organization: Heartland National Tuberculosis Center, San Antonio, Texas, USA – sequence: 7 givenname: Jon surname: Warkentin fullname: Warkentin, Jon organization: Tuberculosis Elimination Program, Tennessee Department of Health, Nashville, Tennessee, USA – sequence: 8 givenname: Pennan surname: Barry fullname: Barry, Pennan organization: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA – sequence: 9 givenname: Neha surname: Shah fullname: Shah, Neha organization: Tuberculosis Control Branch, California Department of Public Health, Richmond, California, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31556947$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkElPwzAQhS1URBe48AOQj1wCtuM4zhGqskhFHGi5Rl4mYJSl9XKAX08EReLwNE9P34xGb44m_dADQueUXFFS5dfG2VFfFeVHaEaLvMxEUdHJPz9F8xA-CKFUkuIETXNaFKLi5Qy93oJV--Ra1wNuBo_jO-CNBxU76CMeGvyU2uisT2-Zh-BCVGO8SRq8Se0wBtj1P0vb3kWw-CWqCOEUHTeqDXB2mAu0vVttlg_Z-vn-cXmzzgwnMmYAjZa5ItQCJ9poIakgZa6KXEhFDKuYKpUoJFWMGU24JCXT499GWAm2ArZAl793d37YJwix7lww0LaqhyGFmrFKUi4Y4SN6cUCT7sDWO-865T_rvy7YNwQOYtg |
| CitedBy_id | crossref_primary_10_1111_jep_14230 crossref_primary_10_1080_14787210_2023_2240022 crossref_primary_10_1080_14737167_2021_1925111 crossref_primary_10_1038_s41598_024_65063_8 crossref_primary_10_1128_aac_01448_22 crossref_primary_10_1186_s12879_022_07693_9 crossref_primary_10_1002_path_5966 crossref_primary_10_1080_14656566_2020_1867538 crossref_primary_10_1007_s44337_025_00493_5 crossref_primary_10_4103_1995_7645_372289 crossref_primary_10_1128_aac_00794_23 crossref_primary_10_2147_IDR_S419996 crossref_primary_10_4103_ijmy_ijmy_95_23 crossref_primary_10_1111_cts_13718 crossref_primary_10_1186_s40249_021_00819_2 crossref_primary_10_1007_s40278_021_88370_5 crossref_primary_10_1155_2024_2037961 crossref_primary_10_1111_jpc_15672 crossref_primary_10_11604_pamj_2024_47_181_34571 crossref_primary_10_1016_j_drudis_2023_103508 crossref_primary_10_1016_j_ijid_2021_07_038 crossref_primary_10_3389_fmed_2023_1304857 crossref_primary_10_52711_2231_5691_2022_00020 |
| ContentType | Journal Article |
| Copyright | Published by Oxford University Press for the Infectious Diseases Society of America 2019. |
| Copyright_xml | – notice: Published by Oxford University Press for the Infectious Diseases Society of America 2019. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/cid/ciz914 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1537-6591 |
| ExternalDocumentID | 31556947 |
| Genre | Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: Intramural CDC HHS grantid: CC999999 – fundername: World Health Organization grantid: 001 |
| GroupedDBID | --- ..I .2P .I3 .ZR 08P 0R~ 29B 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 70D AABZA AACGO AACZT AAJKP AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPLY ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFRAH AFXAL AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQKUS ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HW0 HZ~ IOX J21 JLS JSG JXSIZ KAQDR KBUDW KOP KSI KSN L7B MHKGH MJL ML0 N9A NGC NOMLY NOYVH NPM NU- O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y RD5 ROX ROZ RUSNO RW1 RXO SJN TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ~91 ~S- 7X8 |
| ID | FETCH-LOGICAL-c408t-eefb83a01de40bcb6816073a5368a0c292a7a6581a22cb048072b947c6d8ed9e2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 32 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000577168700016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1537-6591 |
| IngestDate | Sun Sep 28 00:23:12 EDT 2025 Mon Jul 21 05:42:45 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | treatment adverse event multidrug-resistant tuberculosis bedaquiline outcome |
| Language | English |
| License | Published by Oxford University Press for the Infectious Diseases Society of America 2019. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c408t-eefb83a01de40bcb6816073a5368a0c292a7a6581a22cb048072b947c6d8ed9e2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://academic.oup.com/cid/article-pdf/71/4/1010/33653997/ciz914.pdf |
| PMID | 31556947 |
| PQID | 2298146204 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2298146204 pubmed_primary_31556947 |
| PublicationCentury | 2000 |
| PublicationDate | 20200814 |
| PublicationDateYYYYMMDD | 2020-08-14 |
| PublicationDate_xml | – month: 8 year: 2020 text: 20200814 day: 14 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical infectious diseases |
| PublicationTitleAlternate | Clin Infect Dis |
| PublicationYear | 2020 |
| SSID | ssj0011805 |
| Score | 2.5009828 |
| Snippet | In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1010 |
| SubjectTerms | Antitubercular Agents - adverse effects Diarylquinolines - adverse effects Humans Retrospective Studies Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy United States - epidemiology |
| Title | Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31556947 https://www.proquest.com/docview/2298146204 |
| Volume | 71 |
| WOSCitedRecordID | wos000577168700016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1LS8QwEICDuiJefD_WFxG8hm2TbJucRMXFyy57WGVvJZmksiDtvurBX2-StngSBC89BELLZJJ-88gMQndxDirhghEJwAlnVBNfDZfEIoWcMcpUlIdmE-loJKZTOW4cbqsmrbI9E8NBbUrwPvIepdJ7q2jE7-cL4rtG-ehq00JjE3WYQxmf0pVOf6IIsQgpjG5TpyTpy7gtTypZD9xSw-xL-ts7v6Fl-MUM9v_7cQdor4FL_FBrwyHasMUR2hk24fNj9PZojVpUM4-W2NEqdvSHJ22qOS5zHO7jmmX1TpwZ7tHSDU8qbZdQfZRuAM-KMKlGVVyj6gl6HTxPnl5I01iBAI_Emliba-FWITaWRxp0InyZOab6LBEqAiqpSpVDk1hRCjrcOqda8hQSI6yRlp6iraIs7DnCpm8jo7hQEAPXOteRdkYSF4mwGihVXXTbSixziuujEaqwZbXKfmTWRWe12LN5XWEjY45yEvfCiz_MvkS71NvAvkwtv0Kd3G1be4224XM9Wy1vgka452g8_AbtK8Ik |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bedaquiline+for+the+Treatment+of+Multidrug-resistant+Tuberculosis+in+the+United+States&rft.jtitle=Clinical+infectious+diseases&rft.au=Mase%2C+Sundari&rft.au=Chorba%2C+Terence&rft.au=Parks%2C+Samuel&rft.au=Belanger%2C+Ann&rft.date=2020-08-14&rft.eissn=1537-6591&rft.volume=71&rft.issue=4&rft.spage=1010&rft_id=info:doi/10.1093%2Fcid%2Fciz914&rft_id=info%3Apmid%2F31556947&rft_id=info%3Apmid%2F31556947&rft.externalDocID=31556947 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6591&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6591&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6591&client=summon |